Aura Biosciences, Inc. (AURA)
Largest Insider Buys in Sector
AURA Stock Price History Chart
AURA Stock Performance
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Aura Biosciences, Inc.
Over the last 12 months, insiders at Aura Biosciences, Inc. have bought $15.06M and sold $1.09M worth of Aura Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Aura Biosciences, Inc. have bought $16.34M and sold $436,140 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Matrix Capital Management Company, LP (10 percent owner) — $28.08M. Johnson David Michael (director) — $2.05M.
The last purchase of 1,560,000 shares for transaction amount of $14.04M was made by Matrix Capital Management Company, LP (10 percent owner) on 2023‑11‑09.
List of Insider Buy and Sell Transactions, Aura Biosciences, Inc.
| 2024-10-29 | Sale | See Remarks | 9,200 0.0186% | $10.74 | $98,788 | -4.16% | ||
| 2024-10-29 | Sale | Vice President, Finance | 553 0.0011% | $10.74 | $5,938 | -4.16% | ||
| 2024-10-18 | Sale | See Remarks | 24,992 0.0517% | $12.04 | $300,839 | -11.41% | ||
| 2024-10-18 | Sale | Chief Financial Officer | 25,131 0.0519% | $12.03 | $302,361 | -11.41% | ||
| 2024-10-16 | Sale | Chief Technology Officer | 7,383 0.0163% | $9.85 | $72,723 | +1.46% | ||
| 2024-01-23 | Sale | See Remarks | 15,853 0.0323% | $7.64 | $121,141 | +2.61% | ||
| 2024-01-23 | Sale | Chief Financial Officer | 6,609 0.0135% | $7.64 | $50,521 | +2.61% | ||
| 2023-11-09 | 10 percent owner | 1.56M 5.251% | $9.00 | $14.04M | +13.85% | |||
| 2023-11-08 | director | 19,601 0.0517% | $7.30 | $143,087 | +11.25% | |||
| 2023-11-07 | director | 123,000 0.3185% | $7.17 | $881,910 | +12.66% | |||
| 2023-11-06 | Sale | See Remarks | 7,449 0.0211% | $12.03 | $89,611 | -28.10% | ||
| 2023-11-06 | Sale | Chief Financial Officer | 3,900 0.0111% | $12.07 | $47,054 | -28.10% | ||
| 2023-10-30 | Sale | See Remarks | 9,586 0.0229% | $6.83 | $65,478 | +7.23% | ||
| 2023-10-30 | Sale | Chief Financial Officer | 3,385 0.0081% | $6.82 | $23,091 | +7.23% | ||
| 2023-10-04 | director | 6,566 0.0178% | $8.61 | $56,512 | -7.88% | |||
| 2023-10-03 | director | 13,500 0.0352% | $8.27 | $111,663 | -6.59% | |||
| 2023-01-06 | director | 904 0.0024% | $10.51 | $9,501 | -3.81% | |||
| 2023-01-05 | director | 396 0.001% | $10.00 | $3,960 | -2.60% | |||
| 2022-12-28 | director | 2,000 0.0066% | $9.75 | $19,500 | +3.45% | |||
| 2022-12-05 | director | 1.25M 4.0472% | $12.00 | $15M | -16.68% |
Insider Historical Profitability
| Matrix Capital Management Company, LP | 10 percent owner | 6922870 13.9557% | $11.08 | 3 | 0 | <0.0001% |
| Johnson David Michael | director | 135667 0.2735% | $11.08 | 9 | 0 | <0.0001% |
| Medicxi Ventures Management (Jersey) Ltd | director | 2969352 5.9859% | $11.08 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Matrix Capital Management Company, L.P. | $54.34M | 13.97 | 6.92M | 0% | +$0 | 0.51 | |
| Eventide Asset Management | $45.55M | 11.71 | 5.8M | 0% | +$0 | 0.74 | |
| Adage Capital Partners Gp L L C | $35.05M | 9.01 | 4.46M | +5.68% | +$1.88M | 0.06 | |
| Citadel Advisors LLC | $28.86M | 7.42 | 3.68M | +1.24% | +$353,077.30 | 0.02 | |
| Medicxi Growth I Lp | $23.86M | 6.14 | 3.04M | 0% | +$0 | 5.31 |